Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

ADDED NEWS

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

▪️ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:
▪️A favorable safety profile and tolerability across four ascending dose levels
▪️Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
Potential for target engagement in Alzheimer's patients

▪️PMN310 was well-tolerated with no serious adverse events observed. The antibody demonstrated dose proportionality in CSF and a half-life of approximately 25 days, supporting monthly dosing. ProMIS plans to advance PMN310 into a Phase 1b study in Alzheimer's patients in the second half of 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
6
Translate
Report
797 Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1099Followers
69Following
7615Visitors
Follow